An Update on the Potential Roles of E2F Family Members in Colorectal Cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143(3):844–857. doi:10.1053/j.gastro.2012.06.00122763141
   PubMed Web of Science ®Google Scholar
• Hohla F, Winder T, Greil R, et al. Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. World J Gastroenterol. 2014;20(20):6102–6112. doi:10.3748/wjg.v20.i20.610224876732
   PubMed Web of Science ®Google Scholar
• Colvin H, Mizushima T, Eguchi H, et al. Gastroenterological surgery in Japan: the past, the present and the future. Ann Gastroenterol Surg. 2017;1(1):5–10. doi:10.1002/ags3.1200829863129
   PubMed Web of Science ®Google Scholar
• Xanthoulis A, Tiniakos DG. E2F transcription factors and digestive system malignancies: how much do we know? World J Gastroenterol. 2013;19(21):3189–3198. doi:10.3748/wjg.v19.i21.318923745020
   PubMed Web of Science ®Google Scholar
• Araki K, Kawauchi K, Sugimoto W, et al. Mitochondrial protein E2F3d, a distinctive E2F3 product, mediates hypoxia-induced mitophagy in cancer cells. Commun Biol. 2019;2(1):3. doi:10.1038/s42003-018-0246-930740539
   PubMed Web of Science ®Google Scholar
• Liu ZL, Bi XW, Liu PP, et al. Expressions and prognostic values of the E2F transcription factors in human breast carcinoma. Cancer Manag Res. 2018;10:3521–3532. doi:10.2147/CMAR.S17233230271201
   PubMed Web of Science ®Google Scholar
• Wu L, Timmers C, Maiti B, et al. The E2F1-3 transcription factors are essential for cellular proliferation. Nature. 2001;414(6862):457–462. doi:10.1038/3510659311719808
   PubMed Web of Science ®Google Scholar
• Kent LN, Leone G. The broken cycle: E2F dysfunction in cancer. Nat Rev Cancer. 2019;19(6):326–338. doi:10.1038/s41568-019-0143-731053804
   PubMed Web of Science ®Google Scholar
• Ginsberg D. E2F1 pathways to apoptosis. FEBS Lett. 2002;529(1):122–125. doi:10.1016/S0014-5793(02)03270-212354623
   PubMed Web of Science ®Google Scholar
• Dimri GP, Itahana K, Acosta M, et al. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14 ARF tumor suppressor. Mol Cell Biol. 2000;20(1):273–285. doi:10.1128/MCB.20.1.273-285.200010594030
   PubMed Web of Science ®Google Scholar
• Stevens C, La Thangue NB. The emerging role of E2F-1 in the DNA damage response and checkpoint control. DNA Repair. 2004;3(8–9):1071–1079. doi:10.1016/j.dnarep.2004.03.03415279795
   PubMed Web of Science ®Google Scholar
• Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene. 2005;24(17):2810–2826. doi:10.1038/sj.onc.120861215838517
   PubMed Web of Science ®Google Scholar
• Kovesdi I, Reichel R, Nevins JR. Identification of a cellular transcription factor involved in E1A trans-activation. Cell. 1986;45(2):219–228. doi:10.1016/0092-8674(86)90386-72938741
   PubMed Web of Science ®Google Scholar
• Ma H, Hao Y, Dong X, et al. Molecular mechanisms and function prediction of long noncoding RNA. Sci World J. 2012;2012:541786. doi:10.1100/2012/541786
   Web of Science ®Google Scholar
• Gao H, Song X, Kang T, et al. Long noncoding RNA CRNDE functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. Onco Targets Ther. 2017;10:205–216. doi:10.2147/OTT.S11617828115855
   PubMed Web of Science ®Google Scholar
• Yu C, Sun J, Leng X, et al. Long noncoding RNA SNHG6 functions as a competing endogenous RNA by sponging miR-181a-5p to regulate E2F5 expression in colorectal cancer. Cancer Manag Res. 2019;11:611–624. doi:10.2147/CMAR.S18271930666158
   PubMed Web of Science ®Google Scholar
• Ye Y, Gu B, Wang Y, et al. E2F1-mediated MNX1-AS1-miR-218-5p-SEC61A1 feedback loop contributes to the progression of colon adenocarcinoma. J Cell Biochem. 2019;120(4):6145–6153. doi:10.1002/jcb.2790230362161
   PubMed Web of Science ®Google Scholar
• Ohtsuka M, Ling H, Ivan C, et al. H19 noncoding RNA, an independent prognostic factor, regulates essential Rb-E2F and CDK8-β-catenin signaling in colorectal cancer. EBioMedicine. 2016;13:113–124. doi:10.1016/j.ebiom.2016.10.02627789274
   PubMed Web of Science ®Google Scholar
• Zhao JP, Chen LL. Circular RNA MAT2B induces colorectal cancer proliferation via sponging miR-610, resulting in an increased E2F1 expression. Cancer Manag Res. 2020;12:7107–7116. doi:10.2147/CMAR.S25118032848465
   PubMed Web of Science ®Google Scholar
• Xie H, Ren X, Xin S, et al. Emerging roles of circRNA_001569 targeting miR-145 in the proliferation and invasion of colorectal cancer. Oncotarget. 2016;7(18):26680–26691. doi:10.18632/oncotarget.858927058418
   PubMed Web of Science ®Google Scholar
• Zhou C, Liu HS, Wang FW, et al. circCAMSAP1 promotes tumor growth in colorectal cancer via the miR-328-5p/E2F1 axis. Mol Ther. 2020;28(3):914–928. doi:10.1016/j.ymthe.2019.12.00831951832
   PubMed Web of Science ®Google Scholar
• Ungerbäck J, Belenki D, Jawad ul-Hassan A, et al. Genetic variation and alterations of genes involved in NFκB/TNFAIP3- and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer. Carcinogenesis. 2012;33(11):2126–2134. doi:10.1093/carcin/bgs25622843550
   PubMed Web of Science ®Google Scholar
• Morimoto Y, Mizushima T, Wu X, et al. miR-4711-5p regulates cancer stemness and cell cycle progression via KLF5, MDM2 and TFDP1 in colon cancer cells. Br J Cancer. 2020;122(7):1037–1049. doi:10.1038/s41416-020-0758-132066912
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233. doi:10.1016/j.cell.2009.01.00219167326
   PubMed Web of Science ®Google Scholar
• Nakaoka T, Saito Y, Shimamoto Y, et al. Cluster microRNAs miR-194 and miR-215 suppress the tumorigenicity of intestinal tumor organoids. Cancer Sci. 2017;108(4):678–684. doi:10.1111/cas.1316528092415
   PubMed Web of Science ®Google Scholar
• Gao Y, Feng B, Lu L, et al. MiRNAs and E2F3: a complex network of reciprocal regulations in human cancers. Oncotarget. 2017;8(36):60624–60639. doi:10.18632/oncotarget.1736428947999
   PubMedGoogle Scholar
• Huang Y, Chi C. Glioma cell proliferation is inhibited by miR-342-3p, miR-377/E2F1 signaling pathway. Neoplasma. 2019;66(4):524–531. doi:10.4149/neo_2018_180805N57430868897
   PubMed Web of Science ®Google Scholar
• Fang Z, Yang H, Chen D, et al. YY1 promotes colorectal cancer proliferation through the miR-526b-3p/E2F1 axis. Am J Cancer Res. 2019;9(12):2679–2692.31911854
   PubMed Web of Science ®Google Scholar
• Kanaan Z, Rai SN, Eichenberger MR, et al. Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer. Hum Mutat. 2012;33(3):551–560. doi:10.1002/humu.2202122241525
   PubMed Web of Science ®Google Scholar
• Christensen LL, Tobiasen H, Holm A, et al. MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer. Int J Cancer. 2013;133(1):67–78. doi:10.1002/ijc.2801023280316
   PubMed Web of Science ®Google Scholar
• Huang Q, Ma Q. MicroRNA-106a inhibits cell proliferation and induces apoptosis in colorectal cancer cells. Oncol Lett. 2018;15(6):8941–8944. doi:10.3892/ol.2018.851629805629
   PubMed Web of Science ®Google Scholar
• Li T, Luo W, Liu K, et al. miR-31 promotes proliferation of colon cancer cells by targeting E2F2. Biotechnol Lett. 2015;37(3):523–532. doi:10.1007/s10529-014-1715-y25362258
   PubMed Web of Science ®Google Scholar
• Li T, Yang J, Lv X, et al. miR-155 regulates the proliferation and cell cycle of colorectal carcinoma cells by targeting E2F2. Biotechnol Lett. 2014;36(9):1743–1752. doi:10.1007/s10529-014-1540-324793496
   PubMed Web of Science ®Google Scholar
• Yang B, Du K, Yang C, et al. CircPRMT5 circular RNA promotes proliferation of colorectal cancer through sponging miR-377 to induce E2F3 expression. J Cell Mol Med. 2020;24(6):3431–3437. doi:10.1111/jcmm.1501932020730
   PubMed Web of Science ®Google Scholar
• Fang Y, Gu X, Li Z, et al. miR-449b inhibits the proliferation of SW1116 colon cancer stem cells through downregulation of CCND1 and E2F3 expression. Oncol Rep. 2013;30(1):399–406. doi:10.3892/or.2013.246523674142
   PubMed Web of Science ®Google Scholar
• Chang SW, Yue J, Wang BC, et al. miR-503 inhibits cell proliferation and induces apoptosis in colorectal cancer cells by targeting E2F3. Int J Clin Exp Pathol. 2015;8(10):12853–12860.26722476
   PubMed Web of Science ®Google Scholar
• Jiang H, Ge F, Hu B, et al. rs35301225 polymorphism in miR-34a promotes development of human colon cancer by deregulation of 3′UTR in E2F1 in Chinese population. Cancer Cell Int. 2017;17(1):39. doi:10.1186/s12935-017-0402-128293146
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wang J, Li N, et al. miR-34a increases the sensitivity of colorectal cancer cells to 5-fluorouracil in vitro and in vivo. Am J Cancer Res. 2018;8(2):280–290.29511598
   PubMed Web of Science ®Google Scholar
• Akao Y, Noguchi S, Iio A, et al. Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett. 2011;300(2):197–204. doi:10.1016/j.canlet.2010.10.00621067862
   PubMed Web of Science ®Google Scholar
• Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17(2):193–199. doi:10.1038/cdd.2009.5619461653
   PubMed Web of Science ®Google Scholar
• Kiyonari S, Iimori M, Matsuoka K, et al. The 1,2-diaminocyclohexane carrier ligand in oxaliplatin induces p53-dependent transcriptional repression of factors involved in thymidylate biosynthesis. Mol Cancer Ther. 2015;14(10):2332–2342. doi:10.1158/1535-7163.MCT-14-074826208523
   PubMed Web of Science ®Google Scholar
• Aherne ST, Madden SF, Hughes DJ, et al. Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression. BMC Cancer. 2015;15(1):329. doi:10.1186/s12885-015-1327-525924769
   PubMed Web of Science ®Google Scholar
• Li D, Li L. MicroRNA-3666 inhibits breast cancer cell proliferation by targeting sirtuin 7. Mol Med Rep. 2017;16(6):8493–8500. doi:10.3892/mmr.2017.760328944911
   PubMed Web of Science ®Google Scholar
• Wang G, Cai C, Chen L. MicroRNA-3666 regulates thyroid carcinoma cell proliferation via MET. Cell Physiol Biochem. 2016;38(3):1030–1039. doi:10.1159/00044305426937629
   PubMedGoogle Scholar
• Liu W, Song Y, Zhang C, et al. The protective role of all-transretinoic acid (ATRA) against colorectal cancer development is achieved via increasing miR-3666 expression and decreasing E2F7 expression. Biomed Pharmacother. 2018;104:94–101. doi:10.1016/j.biopha.2018.05.01529772445
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li J, Huang Y, et al. Upregulated miR-1258 regulates cell cycle and inhibits cell proliferation by directly targeting E2F8 in CRC. Cell Prolif. 2018;51(6):e12505. doi:10.1111/cpr.1250530144184
   PubMed Web of Science ®Google Scholar
• Liu J, Li X, Wang M, et al. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer. Int J Oncol. 2018;53(4):1601–1612. doi:10.3892/ijo.2018.449230066905
   PubMed Web of Science ®Google Scholar
• Guo X, Liu L, Zhang Q, et al. E2F7 transcriptionally inhibits MicroRNA-199b expression to promote USP47, thereby enhancing colon cancer tumor stem cell activity and promoting the occurrence of colon cancer. Front Oncol. 2020;10:565449. doi:10.3389/fonc.2020.56544933489876
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–10518. doi:10.1073/pnas.080454910518663219
   PubMed Web of Science ®Google Scholar
• Hong DS, Kang YK, Borad M, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020;122(11):1630–1637. doi:10.1038/s41416-020-0802-132238921
   PubMed Web of Science ®Google Scholar
• Wang C, Chen L, Hou X, et al. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol. 2006;8(9):1025–1031. doi:10.1038/ncb146816892051
   PubMed Web of Science ®Google Scholar
• Ianari A, Gallo R, Palma M, et al. Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage. J Biol Chem. 2004;279(29):30830–30835. doi:10.1074/jbc.M40240320015123636
   PubMed Web of Science ®Google Scholar
• Cartier J, Berthelet J, Marivin A, et al. Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 transcription factor-mediated control of cyclin transcription. J Biol Chem. 2011;286(30):26406–26417. doi:10.1074/jbc.M110.19123921653699
   PubMed Web of Science ®Google Scholar
• Johnson J, Thijssen B, McDermott U, et al. Targeting the RB-E2F pathway in breast cancer. Oncogene. 2016;35(37):4829–4835. doi:10.1038/onc.2016.3226923330
   PubMed Web of Science ®Google Scholar
• Meng LH, Zhang H, Hayward L, et al. Tetrandrine induces early G1 arrest in human colon carcinoma cells by down-regulating the activity and inducing the degradation of G1-S-specific cyclin-dependent kinases and by inducing p53 and p21Cip1. Cancer Res. 2004;64(24):9086–9092. doi:10.1158/0008-5472.CAN-04-031315604277
   PubMed Web of Science ®Google Scholar
• Patnaik A, Rosen LS, Tolaney SM, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 2016;6(7):740–753. doi:10.1158/2159-8290.CD-16-009527217383
   PubMed Web of Science ®Google Scholar
• Nagaraju GP, Alese OB, Landry J, et al. HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy. Oncotarget. 2014;5(20):9980–9991. doi:10.18632/oncotarget.248425296971
   PubMedGoogle Scholar
• Zhang J, Zhou L, Zhao S, et al. The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia. Cell Cycle. 2017;16(12):1193–1200. doi:10.1080/15384101.2017.132000528486050
   PubMed Web of Science ®Google Scholar
• Cheong JK, Gunaratnam L, Zang ZJ, et al. TRIP-Br2 promotes oncogenesis in nude mice and is frequently overexpressed in multiple human tumors. J Transl Med. 2009;7(1):8. doi:10.1186/1479-5876-7-819152710
   PubMed Web of Science ®Google Scholar
• Cao Z, Li X, Li J, et al. X-linked inhibitor of apoptosis protein (XIAP) lacking RING domain localizes to the nuclear and promotes cancer cell anchorage-independent growth by targeting the E2F1/Cyclin E axis. Oncotarget. 2014;5(16):7126–7137. doi:10.18632/oncotarget.222725216527
   PubMedGoogle Scholar
• Peng X, Pan K, Zhao W, et al. NPTX1 inhibits colon cancer cell proliferation through down-regulating cyclin A2 and CDK2 expression. Cell Biol Int. 2018;42(5):589–597. doi:10.1002/cbin.1093529345391
   PubMed Web of Science ®Google Scholar
• Li SZ, Zeng F, Li J, et al. Nemo-like kinase (NLK) primes colorectal cancer progression by releasing the E2F1 complex from HDAC1. Cancer Lett. 2018;431:43–53. doi:10.1016/j.canlet.2018.05.03229803790
   PubMed Web of Science ®Google Scholar
• Wu Z, Zheng S, Li Z, et al. E2F1 suppresses Wnt/β-catenin activity through transactivation of β-catenin interacting protein ICAT. Oncogene. 2011;30(37):3979–3984. doi:10.1038/onc.2011.12921532622
   PubMed Web of Science ®Google Scholar
• Kang DW, Choi CY, Cho YH, et al. Targeting phospholipase D1 attenuates intestinal tumorigenesis by controlling β-catenin signaling in cancer-initiating cells. J Exp Med. 2015;212(8):1219–1237. doi:10.1084/jem.2014125426122663
   PubMed Web of Science ®Google Scholar
• Kang DW, Lee BH, Suh YA, et al. Phospholipase D1 inhibition linked to upregulation of ICAT blocks colorectal cancer growth hyperactivated by Wnt/β-catenin and PI3K/Akt signaling. Clin Cancer Res. 2017;23(23):7340–7350. doi:10.1158/1078-0432.CCR-17-074928939743
   PubMed Web of Science ®Google Scholar
• Kang DW, Lee SW, Hwang WC, et al. Phospholipase D1 acts through Akt/TopBP1 and RB1 to regulate the E2F1-dependent apoptotic program in cancer cells. Cancer Res. 2017;77(1):142–152. doi:10.1158/0008-5472.CAN-15-303227793841
   PubMed Web of Science ®Google Scholar
• Birkenkamp-Demtröder K, Hahn SA, Mansilla F, et al. Keratin23 (KRT23) knockdown decreases proliferation and affects the DNA damage response of colon cancer cells. PLoS One. 2013;8(9):e73593. doi:10.1371/journal.pone.007359324039993
   PubMed Web of Science ®Google Scholar
• Ress AL, Stiegelbauer V, Schwarzenbacher D, et al. Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer. Oncotarget. 2014;5(18):8492–8502. doi:10.18632/oncotarget.232925261368
   PubMedGoogle Scholar
• de la Cueva A, Ramírez de Molina A, Alvarez-Ayerza N, et al. Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts. PLoS One. 2013;8(6):e64961. doi:10.1371/journal.pone.006496123762272
   PubMed Web of Science ®Google Scholar
• Tammali R, Ramana KV, Singhal SS, et al. Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells. Cancer Res. 2006;66(19):9705–9713. doi:10.1158/0008-5472.CAN-06-210517018629
   PubMed Web of Science ®Google Scholar
• Ramana KV, Tammali R, Srivastava SK. Inhibition of aldose reductase prevents growth factor-induced G1-S phase transition through the AKT/phosphoinositide 3-kinase/E2F-1 pathway in human colon cancer cells. Mol Cancer Ther. 2010;9(4):813–824. doi:10.1158/1535-7163.MCT-09-079520354121
   PubMed Web of Science ®Google Scholar
• Fang Z, Gong C, Liu H, et al. E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2. Biochem Biophys Res Commun. 2015;464(2):407–415. doi:10.1016/j.bbrc.2015.06.10326093293
   PubMed Web of Science ®Google Scholar
• Kofunato Y, Kumamoto K, Saitou K, et al. UHRF1 expression is upregulated and associated with cellular proliferation in colorectal cancer. Oncol Rep. 2012;28(6):1997–2002. doi:10.3892/or.2012.206423023523
   PubMed Web of Science ®Google Scholar
• Ray RM, Bhattacharya S, Johnson LR. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1. Apoptosis. 2011;16(1):35–44. doi:10.1007/s10495-010-0538-020812030
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844–848. doi:10.1126/science.109247214704432
   PubMed Web of Science ®Google Scholar
• Qian W, Zhang Z, Peng W, et al. CDCA3 mediates p21-dependent proliferation by regulating E2F1 expression in colorectal cancer. Int J Oncol. 2018;53(5):2021–2033. doi:10.3892/ijo.2018.453830226575
   PubMed Web of Science ®Google Scholar
• Yang S, Ren X, Liang Y, et al. KNK437 restricts the growth and metastasis of colorectal cancer via targeting DNAJA1/CDC45 axis. Oncogene. 2020;39(2):249–261. doi:10.1038/s41388-019-0978-031477839
   PubMed Web of Science ®Google Scholar
• Ji M, Ren L, Lv Y, et al. Small nuclear ribonucleoprotein polypeptide N accelerates malignant progression and poor prognosis in colorectal cancer transcriptionally regulated by E2F8. Front Oncol. 2020;10:561287. doi:10.3389/fonc.2020.56128733224876
   PubMed Web of Science ®Google Scholar
• Hu ZQ, Xue H, Long JH, et al. Biophysical properties and motility of human mature dendritic cells deteriorated by vascular endothelial growth factor through cytoskeleton remodeling. Int J Mol Sci. 2016;17:11. doi:10.3390/ijms17111756
   Web of Science ®Google Scholar
• Terzić J, Grivennikov S, Karin E, et al. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101–2114.e2105. doi:10.1053/j.gastro.2010.01.05820420949
   PubMed Web of Science ®Google Scholar
• Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011;140(6):1807–1816. doi:10.1053/j.gastro.2011.01.05721530747
   PubMed Web of Science ®Google Scholar
• Shawki S, Ashburn J, Signs SA, et al. Colon cancer: inflammation-associated cancer. Surg Oncol Clin N Am. 2018;27(2):269–287. doi:10.1016/j.soc.2017.11.00329496089
   PubMed Web of Science ®Google Scholar
• Ying L, Marino J, Hussain SP, et al. Chronic inflammation promotes retinoblastoma protein hyperphosphorylation and E2F1 activation. Cancer Res. 2005;65(20):9132–9136. doi:10.1158/0008-5472.CAN-05-135816230367
   PubMed Web of Science ®Google Scholar
• Waldner MJ, Foersch S, Neurath MF. Interleukin-6--a key regulator of colorectal cancer development. Int J Biol Sci. 2012;8(9):1248–1253. doi:10.7150/ijbs.461423136553
   PubMed Web of Science ®Google Scholar
• Lee YS, Choi I, Ning Y, et al. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer. 2012;106(11):1833–1841. doi:10.1038/bjc.2012.17722617157
   PubMed Web of Science ®Google Scholar
• Barderas R, Bartolomé RA, Fernandez-Aceñero MJ, et al. High expression of IL-13 receptor α2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. Cancer Res. 2012;72(11):2780–2790. doi:10.1158/0008-5472.CAN-11-409022505647
   PubMed Web of Science ®Google Scholar
• Hyun YS, Han DS, Lee AR, et al. Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis. 2012;33(4):931–936. doi:10.1093/carcin/bgs10622354874
   PubMed Web of Science ®Google Scholar
• Chen J, Gong C, Mao H, et al. E2F1/SP3/STAT6 axis is required for IL-4-induced epithelial-mesenchymal transition of colorectal cancer cells. Int J Oncol. 2018;53(2):567–578. doi:10.3892/ijo.2018.442929901191
   PubMed Web of Science ®Google Scholar
• Keku TO, Dulal S, Deveaux A, et al. The gastrointestinal microbiota and colorectal cancer. Am J Physiol Gastrointest Liver Physiol. 2015;308(5):G351–G363. doi:10.1152/ajpgi.00360.201225540232
   PubMed Web of Science ®Google Scholar
• Thompson KJ, Ingle JN, Tang X, et al. A comprehensive analysis of breast cancer microbiota and host gene expression. PLoS One. 2017;12(11):e0188873. doi:10.1371/journal.pone.018887329190829
   PubMed Web of Science ®Google Scholar
• Parekh PJ, Balart LA, Johnson DA. The influence of the gut microbiome on obesity, metabolic syndrome and gastrointestinal disease. Clin Transl Gastroenterol. 2015;6(6):e91. doi:10.1038/ctg.2015.1626087059
   PubMed Web of Science ®Google Scholar
• Choi EH, Kim KP. E2F1 facilitates DNA break repair by localizing to break sites and enhancing the expression of homologous recombination factors. Exp Mol Med. 2019;51(9):1–12. doi:10.1038/s12276-019-0307-2
   Web of Science ®Google Scholar
• Yuan J, Narayanan L, Rockwell S, et al. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res. 2000;60(16):4372–4376.10969780
   PubMed Web of Science ®Google Scholar
• Mihaylova VT, Bindra RS, Yuan J, et al. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol Cell Biol. 2003;23(9):3265–3273. doi:10.1128/MCB.23.9.3265-3273.200312697826
   PubMed Web of Science ®Google Scholar
• Bindra RS, Glazer PM. Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutat Res. 2005;569(1–2):75–85. doi:10.1016/j.mrfmmm.2004.03.01315603753
   PubMed Web of Science ®Google Scholar
• Koshiji M, To KK, Hammer S, et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell. 2005;17(6):793–803. doi:10.1016/j.molcel.2005.02.01515780936
   PubMed Web of Science ®Google Scholar
• Bindra RS, Gibson SL, Meng A, et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res. 2005;65(24):11597–11604. doi:10.1158/0008-5472.CAN-05-211916357170
   PubMed Web of Science ®Google Scholar
• Bindra RS, Schaffer PJ, Meng A, et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol. 2004;24(19):8504–8518. doi:10.1128/MCB.24.19.8504-8518.200415367671
   PubMed Web of Science ®Google Scholar
• Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85–95. doi:10.1038/nrc298121258394
   PubMed Web of Science ®Google Scholar
• Tennstedt P, Fresow R, Simon R, et al. RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. Int J Cancer. 2013;132(9):2118–2126. doi:10.1002/ijc.2790723065657
   PubMed Web of Science ®Google Scholar
• Lobo NA, Shimono Y, Qian D, et al. The biology of cancer stem cells. Annu Rev Cell Dev Biol. 2007;23(1):675–699. doi:10.1146/annurev.cellbio.22.010305.10415417645413
   PubMed Web of Science ®Google Scholar
• Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells--perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006;66(19):9339–9344. doi:10.1158/0008-5472.CAN-06-312616990346
   PubMedGoogle Scholar
• Zhu L, Finkelstein D, Gao C, et al. Multi-organ mapping of cancer risk. Cell. 2016;166(5):1132–1146.e1137. doi:10.1016/j.cell.2016.07.04527565343
   PubMed Web of Science ®Google Scholar
• Tomasetti C, Li L, Vogelstein B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science. 2017;355(6331):1330–1334. doi:10.1126/science.aaf901128336671
   PubMed Web of Science ®Google Scholar
• Kent LN, Bae S, Tsai SY, et al. Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma. J Clin Invest. 2017;127(3):830–842. doi:10.1172/JCI8758328134624
   PubMed Web of Science ®Google Scholar
• Thurlings I, Martínez-López LM, Westendorp B, et al. Synergistic functions of E2F7 and E2F8 are critical to suppress stress-induced skin cancer. Oncogene. 2017;36(6):829–839. doi:10.1038/onc.2016.25127452520
   PubMed Web of Science ®Google Scholar
• Brown RE, Short SP, Williams CS. Colorectal cancer and metabolism. Curr Colorectal Cancer Rep. 2018;14(6):226–241. doi:10.1007/s11888-018-0420-y31406492
   PubMed Web of Science ®Google Scholar
• Denechaud PD, Fajas L, Giralt A. E2F1, a novel regulator of metabolism. Front Endocrinol. 2017;8:311. doi:10.3389/fendo.2017.00311
   PubMed Web of Science ®Google Scholar
• Liew CW, Boucher J, Cheong JK, et al. Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance. Nat Med. 2013;19(2):217–226. doi:10.1038/nm.305623291629
   PubMed Web of Science ®Google Scholar
• Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211–218. doi:10.1016/j.tibs.2015.12.00126778478
   PubMed Web of Science ®Google Scholar
• Wu M, Seto E, Zhang J. E2F1 enhances glycolysis through suppressing Sirt6 transcription in cancer cells. Oncotarget. 2015;6(13):11252–11263. doi:10.18632/oncotarget.359425816777
   PubMedGoogle Scholar
• Sanmartín-Salinas P, Lobo M, Noguerales-Fraguas F, et al. Insulin receptor substrate-4 is overexpressed in colorectal cancer and promotes retinoblastoma–cyclin-dependent kinase activation. J Gastroenterol. 2018;53(8):932–944. doi:10.1007/s00535-018-1432-829353348
   PubMed Web of Science ®Google Scholar
• Bochicchio S, Dapas B, Russo I, et al. In vitro and ex vivo delivery of tailored siRNA-nanoliposomes for E2F1 silencing as a potential therapy for colorectal cancer. Int J Pharm. 2017;525(2):377–387. doi:10.1016/j.ijpharm.2017.02.02028189855
   PubMed Web of Science ®Google Scholar
• Lee SR, Jin H, Kim WT, et al. Tristetraprolin activation by resveratrol inhibits the proliferation and metastasis of colorectal cancer cells. Int J Oncol. 2018;53(3):1269–1278. doi:10.3892/ijo.2018.445329956753
   PubMed Web of Science ®Google Scholar
• Kumazaki M, Noguchi S, Yasui Y, et al. Anti-cancer effects of naturally occurring compounds through modulation of signal transduction and miRNA expression in human colon cancer cells. J Nutr Biochem. 2013;24(11):1849–1858. doi:10.1016/j.jnutbio.2013.04.00623954321
   PubMed Web of Science ®Google Scholar
• Bakar-Ates F, Ozkan E. The combined treatment of brassinin and imatinib synergistically downregulated the expression of MMP-9 in SW480 colon cancer cells. Phytother Res. 2019;33(2):397–402. doi:10.1002/ptr.623330450754
   PubMed Web of Science ®Google Scholar
• Varughese RS, Lam WS-T, Marican A, et al. Biopharmacological considerations for accelerating drug development of deguelin, a rotenoid with potent chemotherapeutic and chemopreventive potential. Cancer. 2019;125(11):1789–1798. doi:10.1002/cncr.3206930933320
   PubMed Web of Science ®Google Scholar
• Lee HS, Kim EJ, Kim SH. Ethanol extract of innotus obliquus (Chaga mushroom) induces G1 cell cycle arrest in HT-29 human colon cancer cells. Nutr Res Pract. 2015;9(2):111–116. doi:10.4162/nrp.2015.9.2.11125861415
   PubMed Web of Science ®Google Scholar
• Haydé VC, Ramón GG, Lorenzo GO, et al. Non-digestible fraction of beans (Phaseolus vulgaris L.) modulates signalling pathway genes at an early stage of colon cancer in Sprague-Dawley rats. Br J Nutr. 2012;108(Suppl 1):S145–S154. doi:10.1017/S000711451200078522916810
   PubMed Web of Science ®Google Scholar
• Choi HJ, Lim DY, Park JH. Induction of G1 and G2/M cell cycle arrests by the dietary compound 3,3ʹ-diindolylmethane in HT-29 human colon cancer cells. BMC Gastroenterol. 2009;9:39. doi:10.1186/1471-230X-9-3919480695
   PubMed Web of Science ®Google Scholar
• Choi JK, Murillo G, Su B-N, et al. Ixocarpalactone a isolated from the Mexican tomatillo shows potent antiproliferative and apoptotic activity in colon cancer cells. FEBS J. 2006;273(24):5714–5723. doi:10.1111/j.1742-4658.2006.05560.x17212786
   PubMed Web of Science ®Google Scholar
• Liu H, Liu H, Zhou Z, et al. Herbal formula Huang Qin Ge Gen Tang enhances 5-fluorouracil antitumor activity through modulation of the E2F1/TS pathway. Cell Commun Signal. 2018;16(1):7. doi:10.1186/s12964-018-0218-129458395
   PubMed Web of Science ®Google Scholar
• Kim K-C, Lee C. Curcumin induces downregulation of E2F4 expression and apoptotic cell death in HCT116 human colon cancer cells; involvement of reactive oxygen species. Korean J Physiol Pharmacol. 2010;14(6):391–397. doi:10.4196/kjpp.2010.14.6.39121311680
   PubMed Web of Science ®Google Scholar
• Rajitha B, Belalcazar A, Nagaraju GP, et al. Inhibition of NF-κB translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer. Cancer Lett. 2016;373(2):227–233. doi:10.1016/j.canlet.2016.01.05226850372
   PubMed Web of Science ®Google Scholar
• Gong S, Xu D, Zhu J, et al. Efficacy of the MEK inhibitor cobimetinib and its potential application to colorectal cancer cells. Cell Physiol Biochem. 2018;47(2):680–693. doi:10.1159/00049002229794421
   PubMedGoogle Scholar
• Park HY, Park S-H, Jeong J-W, et al. Induction of p53-independent apoptosis and G1 cell cycle arrest by fucoidan in HCT116 human colorectal carcinoma cells. Mar Drugs. 2017;15(6):6. doi:10.3390/md15060154
   Web of Science ®Google Scholar
• Mujumdar N, Mackenzie TN, Dudeja V, et al. Triptolide induces cell death in pancreatic cancer cells by apoptotic and autophagic pathways. Gastroenterology. 2010;139(2):598–608. doi:10.1053/j.gastro.2010.04.04620434451
   PubMed Web of Science ®Google Scholar
• Oliveira A, Beyer G, Chugh R, et al. Triptolide abrogates growth of colon cancer and induces cell cycle arrest by inhibiting transcriptional activation of E2F. Lab Invest. 2015;95(6):648–659. doi:10.1038/labinvest.2015.4625893635
   PubMed Web of Science ®Google Scholar
• Su Z, Zhou C, Qin S, et al. The significant pathways and genes underlying the colon cancer treatment by the traditional Chinese medicine PHY906. Evid Based Complement Alternat Med. 2017;2017:8753815. doi:10.1155/2017/875381528588641
   PubMed Web of Science ®Google Scholar
• Zeng H, Cheng W-H, Johnson LK. Methylselenol, a selenium metabolite, modulates p53 pathway and inhibits the growth of colon cancer xenografts in Balb/c mice. J Nutr Biochem. 2013;24(5):776–780. doi:10.1016/j.jnutbio.2012.04.00822841391
   PubMed Web of Science ®Google Scholar
• Fukushima M, Sakamoto K, Ohshimo H, et al. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase. Oncol Rep. 2010;24(4):835–842. doi:10.3892/or.2010.83520811661
   PubMed Web of Science ®Google Scholar
• Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8(1):57–84. doi:10.1177/175883401561453026753006
   PubMed Web of Science ®Google Scholar
• Kasahara M, Takahashi Y, Nagata T, et al. Thymidylate synthase expression correlates closely with E2F1 expression in colon cancer. Clin Cancer Res. 2000;6(7):2707–2711.10914714
   PubMed Web of Science ®Google Scholar
• Intuyod K, Saavedra-García P, Zona S, et al. FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance. Cell Death Dis. 2018;9(12):1185. doi:10.1038/s41419-018-1235-030538221
   PubMed Web of Science ®Google Scholar
• Varghese V, Magnani L, Harada-Shoji N, et al. FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression. Sci Rep. 2019;9(1):1505. doi:10.1038/s41598-018-38017-030728402
   PubMed Web of Science ®Google Scholar
• Cardinale D, Guaitoli G, Tondi D, et al. Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase. Proc Natl Acad Sci U S A. 2011;108(34):E542–E549. doi:10.1073/pnas.110482910821795601
   PubMed Web of Science ®Google Scholar
• Banerjee D, Gorlick R, Liefshitz A, et al. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. Cancer Res. 2000;60(9):2365–2367.10811110
   PubMed Web of Science ®Google Scholar
• Sulzyc-Bielicka V, Domagala P, Bielicki D, et al. E2F1/TS immunophenotype and survival of patients with colorectal cancer treated with 5FU-based adjuvant therapy. Pathol Oncol Res. 2016;22(3):601–608. doi:10.1007/s12253-016-0043-z26831819
   PubMed Web of Science ®Google Scholar
• Liu KP, Luo F, Xie SM, et al. Glycogen synthase kinase 3β inhibitor (2ʹZ,3ʹE)-6-bromo-indirubin- 3ʹ-oxime enhances drug resistance to 5-fluorouracil chemotherapy in colon cancer cells. Chin J Cancer Res. 2012;24(2):116–123. doi:10.1007/s11670-012-0116-923359767
   PubMed Web of Science ®Google Scholar
• Watanabe M, Sowa Y, Yogosawa M, et al. Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells. Cancer Sci. 2013;104(6):687–693. doi:10.1111/cas.1213923438367
   PubMed Web of Science ®Google Scholar
• Lavitrano M, Ianzano L, Bonomo S, et al. BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers. J Pathol. 2020;250(2):134–147. doi:10.1002/path.534731518438
   PubMed Web of Science ®Google Scholar
• Fang Z, Gong C, Yu S, et al. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling. Cancer Lett. 2018;415:58–72. doi:10.1016/j.canlet.2017.11.04029203250
   PubMed Web of Science ®Google Scholar
• Chen B, Wen P, Hu G, et al. Antagonizing CDK8 sensitizes colorectal cancer to radiation through potentiating the transcription of e2f1 target gene apaf1. Front Cell Dev Biol. 2020;8:408. doi:10.3389/fcell.2020.0040832596239
   PubMed Web of Science ®Google Scholar
• Yin J, Shen X, Li M, et al. miR-329 regulates the sensitivity of 5-FU in chemotherapy of colorectal cancer by targeting E2F1. Oncol Lett. 2018;16(3):3587–3592. doi:10.3892/ol.2018.912130127965
   PubMed Web of Science ®Google Scholar
• Lin Z, Ren N, Jiang Y, et al. Adenovirus-mediated E2F-1 gene transfer augments gemcitabine-induced apoptosis in human colon cancer cells. Clin Lab. 2015;61(10):1435–1444. doi:10.7754/Clin.Lab.2015.15010426642705
   PubMed Web of Science ®Google Scholar
• Dong YB, Yang HL, McMasters KM. E2F-1 overexpression sensitizes colorectal cancer cells to camptothecin. Cancer Gene Ther. 2003;10(3):168–178. doi:10.1038/sj.cgt.770056512637937
   PubMed Web of Science ®Google Scholar
• De Leon G, Sherry TC, Krucher NA. Reduced expression of PNUTS leads to activation of Rb-phosphatase and caspase-mediated apoptosis. Cancer Biol Ther. 2008;7(6):833–841. doi:10.4161/cbt.7.6.583918360108
   PubMed Web of Science ®Google Scholar